# Areas of Focus

## What kind of innovation we are looking for in a partner

### Immunology

- Nephrology (eg. Chronic kidney diseases,Immune mediated GN)
- Transplant (eg. Renal transplant)
- Interferon driven inflammatory disease (eg. Lupus Nephritis, Systemic sclerosis)
- Gastroenterology, Respiratory, Rheumatology
  - Innate
  - Tolerance
  - Adaptive
  - Fibrosis
  - Tissue Regeneration Targets

### Neuroscience

- Neurodegeneration (eg. Alzheimer's disease, Parkinson's disease, etc)
- Neuromuscular disorders (eg. Muscular Dystrophy, Becker's, Friedreich's Ataxia)
- Neuroinflammation
- Neurodevelopmental
- Stroke, Psychiatry

### Ophthalmology

- Retinal diseases (Age related macular degeneration, Geographic Atrophy, Diabetic Macular Edema, Diabetic Retinopathy)
- Glaucoma and dry eye disease
- Therapy for front of the eyes

### Rare Diseases

- Monogenetic rare diseases in neuroscience, ophthalmology, and rare blood disease

### Oncology

- Oncogenic drivers
- Synthetic lethality (beyond DNA Damage Response)
- Innate immune cells/pathways (eg. stimulators, inhibitors of suppressiveness)
- Extracellular Matrix (eg. matrix modulation to enhance immune infiltration)
- Gastrointestinal cancers

### Research Technologies

- Degrader antibody conjugate (DAC)
- Antibody prodrug
- Targeted, intracellular delivery
- Artificial intelligence for drug discovery
- Genomic Medicine platforms
- Novel modalities and enabling technologies to expand druggable target space

### Digital Health (Personalized Health)

- Robust data sets
- Advanced Analytics (artificial intelligence incl. machine learning and deep-learning models)
- Digital and mobile technologies

### Infectious Diseases

- Hepatitis B
- Respiratory Viruses
- Multidrug-resistant, Gram-negative
- Bacterial Infections

**Current higher priorities with different color (blue)**

| WHAT WE ARE FOCUSING ON | |
|---|---|
| | Potential for first- or best-in class molecules |
| | Novel targets |
| | Novel enabling modalities |
| | High disease burden |

| WHAT WE ARE LOOKING FOR | |
|---|---|
| | Clear biology |
| | Consistent data |
| | Solid IP |
| | Biomarker strategy |

**Doing now what patients need next**